Shelley Chu
SelectiveNamed in filings at Abingworth BioventuresOn the current fund
- Board seats filed
- 12
- Named on a board
- 2
all filings on record
Named in filings at Abingworth BioventuresOn the current fund
all filings on record
last 24 months
from a verified or cited source
| Odyssey Therapeutics | Biotech & pharma | June 2025 | Caduceus Capital, Orbimed Asia Partners, Orbimed New Horizons, Orbimed Partners |
| Antares Therapeutics | Biotech & pharma | May 2025 | Atlas Venture |
| Seismic Therapeutic | Biotech & pharma | November 2023 | None on file |
| Triana Biomedicines | Biotech & pharma | January 2022 | Atlas Venture, Third Rock Ventures |
| Protego Biopharma | Biotech & pharma | October 2021 | None on file |
| Abata Therapeutics | Biotech & pharma | June 2021 | Third Rock Ventures |
| Enlaza Therapeutics | Biotech & pharma | March 2021 | None on file |
| Scorpion Therapeutics | Biotech & pharma | November 2020 | Atlas Venture |
| IFM Quattro | Biotech & pharma | November 2019 | Atlas Venture |
| IFM Continua | Biotech & pharma | November 2019 | Atlas Venture |
| IFM Cinque | Biotech & pharma | November 2019 | Atlas Venture |
| Venatorx Pharmaceuticals | Biotech & pharma | July 2017 | None on file |
The company and date are what the SEC filing shows, not a statement of investment thesis. A partner can sit on a board for reasons that say nothing about what their firm funds today. The sector is not a filing value: it is Lev’s own classification of each company, shown only when we found a specific, checkable source for it; otherwise it reads “Not yet classified.” “Also on the board from” names another tracked firm with a partner on the same board, both with a clean identity match. It is not a claim either firm led or co-led the round, and “None on file” means no other tracked firm’s partner shares this specific board seat, not that no one else invested. Sorted newest first by default; click a column to change it. Something wrong? Tell us.
Classified sectors of companies where filings name Shelley Chu on the board, based on 12 filed seats with a verified or cited source.